Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Taro Pharmaceuticals USA
ClinicalTrials.gov Identifier:
NCT01788007
First received: February 7, 2013
Last updated: January 19, 2014
Last verified: January 2014
  Purpose

The objective of this study is to compare the relative efficacy and safety of the test formulation Imiquimod 3.75% Topical Cream to the marketed formulation Zyclara® (imiquimod) 3.75% Topical Cream in the treatment of actinic keratosis. Both the test and reference formulations will also be compared to a placebo cream to test for superiority.


Condition Intervention Phase
Actinic Keratosis
Drug: Imiquimod Topical Cream 3.75%
Drug: Zyclara® (imiquimod) Topical Cream 3.75%
Drug: Vehicle Topical Cream
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.

Resource links provided by NLM:


Further study details as provided by Taro Pharmaceuticals USA:

Primary Outcome Measures:
  • Treatment success [ Time Frame: Week 14 (8 weeks after completion of treatment) ] [ Designated as safety issue: No ]
    Treatment success will be defined by the proportion of patients in the per protocol population with 100% clearance of all actinic keratosis lesions within the treatment area at study week 14 (8 weeks after completion of treatment.)


Secondary Outcome Measures:
  • Superiority to placebo [ Time Frame: Week 14 (8 weeks after completion of treatment) ] [ Designated as safety issue: No ]
    The modified intent-to-treat population and last observation carried forward will be used to evaluate the superiority of both the test and reference product to placebo for the proportion of patients showing 100% clearance of actinic keratosis lesions at week 14 (8 weeks after completion of treatment.)


Enrollment: 443
Study Start Date: January 2013
Study Completion Date: December 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Imiquimod Topical Cream 3.75%
Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.)
Drug: Imiquimod Topical Cream 3.75%
Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
Placebo Comparator: Vehicle Topical Cream
Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.)
Drug: Vehicle Topical Cream
Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
Active Comparator: Zyclara® (imiquimod) Topical Cream 3.75%
Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.)
Drug: Zyclara® (imiquimod) Topical Cream 3.75%
Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent form.
  • Immunocompetent male or non-pregnant, non-lactating female at least 18 years of age.
  • Diagnosis of actinic keratosis with at least 5 and no more than 20 clinically typical, visible or palpable actinic keratosis lesions, each at least 4 mm in diameter, in an area that exceeds 25 cm2 on either the face (excluding ear) or balding scalp (but not both.)
  • Women either must be 1 year post-menopausal, surgically sterile, or if they are of child-bearing potential, they must: a) have been using systemic birth control, intrauterine device, or Norplant for at least 28 days prior to the start of treatment period, or used barrier methods consistently, at least 14 days before study cream administration; b) had a normal menstrual cycle for the month prior to the start of treatment; c) have a negative urine pregnancy test result upon entry into the study; d) agree to use a medically accepted form of birth control throughout the study period.
  • Free from any systemic or dermatologic disorder that, in the opinion of the Investigator, will interfere with the study results or increase the risk of adverse events.
  • Any skin type or race, providing the skin pigmentation will allow discernment of erythema.
  • Willingness and capability to cooperate to the extent and degree required by the protocol.

Exclusion Criteria:

  • Presence of atopic dermatitis, basal cell carcinoma, squamous cell carcinoma, eczema, psoriasis, rosacea, sunburn or other possible confounding skin conditions on the face or bald scalp.
  • Use within six months prior to baseline on the face or bald scalp of chemical peel, dermabrasion, laser abrasion, psoralen plus ultraviolet A therapy, or ultra violet B therapy.
  • Use within one month prior to baseline on the face or bald scalp of cryodestruction or chemodestruction, curettage, photodynamic therapy, surgical excision, topical 5-fluorouracil, topical corticosteroids, topical diclofenac, topical imiquimod, topical retinoids or other treatments for actinic keratosis including glycolic acids or over-the-counter products containing retinol, alpha or beta hydroxy acids.
  • Use within one month prior to baseline of immunomodulators or immunosuppressive therapies, interferon, oral corticosteroids or cytotoxic drugs.
  • Known allergies to imiquimod or any excipients to the test or reference creams.
  • Receiving 5-fluorouracil or other systemic cancer chemotherapy within 6 months prior to study entry.
  • Any condition, medical, psychological, or social, that, in the Investigator's opinion, would interfere with participation in the study.
  • Women who are pregnant or planning pregnancy or lactating during the study.
  • Participation in any investigational drug study within 30 days of enrollment or previous participation in this study.
  • Employees or family members of employees of the research center or Investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Taro Pharmaceuticals USA
ClinicalTrials.gov Identifier: NCT01788007     History of Changes
Other Study ID Numbers: IMQC 1220
Study First Received: February 7, 2013
Last Updated: January 19, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Taro Pharmaceuticals USA:
Actinic Keratosis
Imiquimod Topical Cream 3.75%
Zyclara® (imiquimod) Topical Cream 3.75%

Additional relevant MeSH terms:
Keratosis
Keratosis, Actinic
Skin Diseases
Precancerous Conditions
Neoplasms
Imiquimod
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Interferon Inducers

ClinicalTrials.gov processed this record on August 25, 2014